Quipazine: Classical hallucinogen? Novel psychedelic?
Richard A Glennon, Małgorzata Dukat
Australian Journal of Chemistry July 17, 2023 DOI: 10.1071/ch22256 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Quipazine has not been tested in humans, so it cannot be classified as a psychedelic agent despite preclinical evidence, and its 5-HT3 receptor activity may cause emesis in future studies. |
Abstract
Quipazine, first identified in the 1960s, has been the topic of >1000 published papers. On the basis of available 5-HT2 serotonin receptor radioligand binding data and various preclinical studies, it might be thought that quipazine bears the hallmarks of a classical hallucinogen or psychedelic agent – agents currently being examined for their potential use in treating certain neuropsychiatric disorders. Nevertheless, by definition, such agents require the availability of human data, which, in the case of quipazine, are lacking. Because quipazine is also a 5-HT3 receptor agonist, future human studies with this agent might prove problematic because 5-HT3 agonists are known to produce emesis. Nevertheless, continued investigation of novel quipazine analogs with modified pharmacological profiles might prove worthwhile.